(Technically taken from a book report I wrote for my Biotechnology Intellectual Property class...)
The most refreshing part of
More
than Human by Ramez Naam is the tone and point of view. Mr. Naam is upbeat
and positive about the future of genetic and prosthetic research, and the
incorporation of those technologies in both treatment of disease and future use
in human enhancement. The book, published in 2005, will always suffer from
being frozen in time acting as a bookmark in human technological and medical
developments because some of the research mentioned in the book will come to fruition
and other research will have been abandoned.
I share Mr. Naam’s worries
regarding regulation being imposed that would impede progress. I disagree that
this poses a significant barrier to the further development of these
technologies or their use in human enhancement. Simply, these technologies will
provide a competitive edge for those who are able to successfully implement
them. Anything that reduces health care needs, increases human strength and
longevity (and thereby the useful working life of an individual), or a computer
implant that allows for better communication, memory, or faster calculations will
necessarily be implemented.
The largest barriers in the United
States are likely to be a lack of allocated funding by the government and
resistance from members of the Religious Right who would see such enhancement
as ‘defiling the sanctity of the human body.’ Such notions are likely to
provide great resistance to early adoption and may even lead to such technology
being outlawed. Once the competitive edge and benefits are proven on foreign
soil it will not stop those who can afford such procedures from obtaining them
or a black market arising to cater to the demand. At this point the government
will be forced both to legalize and attempt to regulate such enhancements or to
dedicate resources in an attempt to stop all such implementation. Attempting to
stop all implementation would likely meet with similar results to “The War on
Drugs” which has met with limited success abroad and led to a large healthy
black market domestically.
The issue of funding will be the
second large hurdle in the United States. There is a lot of money in
pharmaceuticals and health care. From a profitability standpoint they are
interested in demand for their product. Permanent immunity or curing of a
disease is less profitable for those corporations than a onetime cure or
treatment. It will come down to a cost benefit analysis regarding the potential
profits of a onetime treatment applicable to the effected population versus a
recurring treatment that provides a constant revenue stream. With the current
state of corporate law and Citizens United as a standing decision it is
the duty of the corporation to maximize shareholder profit and when practicable,
an obligation for a corporation to lobby Congress in such a way as to keep the
business profitable. Lobbying will likely result in less funding towards
permanent cures and preventative treatments, unless such treatments can be
mandated to the population as a whole, this would interfere with First
Amendment rights and personal autonomy. Basically, if there is no profit in it,
private industry will not stand behind it. This scenario would be less likely
to play out in a country with nationalized or socialized health care. Research
can be conducted at the tax payer’s expense and the implementation, which would
result in lower private profits and lower public costs would more likely be
pursued. The result is that preventative and permanent genetic treatments are
likely to rise outside the United States and may not be adopted until they are
necessary to remain competitive in the global markets.
The technology described by Mr.
Naam, as stated before, is a bit dated at times. Some things have taken new directions.
Things I wish he had discussed more were brain plasticity and the limitations
presented between humans and prosthetic devices, including implants, by
bandwidth. One great hurdle as we are able to increase sensor density and
create bio-inert implants and interfaces with the nervous system will be
whether we overload the natural bandwidth of such nerve bundles and fibers and
how we will get around them. Granted, at the time the book was written, it
seemed like one or eight electrodes was a lot, and not with ever decreasing
silicon printing size, and the accompanying transistor and microchip densities,
such interfaces seem obsolete.
The most important point that Mr.
Naam makes is that we need to fund research into both the curative applications
of biotechnology and genetic treatments as well as their potentials for human
enhancement. A problem he brings up, and that cannot be stressed enough, is
that technologies and treatments, like EPO are out there and used medically but
have potential to be used for enhancement. Without research into the enhancing
properties such technologies they will continue to be used at great risk to the
user because little is known of what amounts are safe. It will be safer for the
general population to know the safe uses and risks rather than operating
blindly in ignorance.
The most optimistic points of the
book were in the paragraphs describing successful human application. The use of
gene therapy to cure a little girl’s disease in India and allowing her to
recover something so completely debilitating that her life was forfeit and now
she has enjoyed a normal childhood. There is a man who had an implant and can
now communicate with text, something that would benefit from cellphone
technologies such as T9, allowing predictive words and faster typing. These are
the beginnings of developments that will allow for future human computer
interface and pave the way for gene therapy in order to treat disease and
individual’s genetic flaws. One thought that Mr. Naam presents, and one that
studying biomedical engineering and these potentials I had not considered is
that any given enhancing gene may come some detriment such that a “perfect
human” could not be created but that we could choose certain propensities while
sacrificing others. This gives strong encouragement to map the genome and to
know as much as possible about the gene’s effects.
This book provides an optimistic
outlook for future human use of genetic engineering and treatment as well as
human and computer integration. It is a photograph of one point in time, that
hopefully we will surpass its expectations. At the very least, it is nice to
have a public opinion out there encouraging a march towards progress rather
than debating whether we can still go forward and remain “human.” One thing
Ramez Naam says loud and clear throughout More than Human is: ‘Go
forward humanity, toward progress!’
Key point I missed in the report:
In the book there is a discussion about hypothetical cloning of humans. Which, sounds really interesting. Most naysayers are against this because it will result in a copy of a person walking around. One that will be a "clone." While genetically it is true, they will be a clone the reality is that such a person, say born 10 or 20 years later than their genetic original will grow up in a different world, a different environment, and so on. More so, if we can use genetic engineering to eliminate diseases and genetic defects as we go along, all the better. To me, at the moment, my main objection comes from lack of methods for revitalizing the DNA we would be cloning from. Basically, right now you clone something and it is the age of the original's DNA only in a developing body that is undergoing very high rates of cell division (also known as a bad idea). So... technically it's a moot point at the moment because we're not technologically where we need to be for it to work.
As for cloning organs to greatly reduce biological rejection I am all for it!